{"drugs":["Ertapenem Sodium","INVanz"],"mono":{"0":{"id":"926936-s-0","title":"Generic Names","mono":"Ertapenem Sodium"},"1":{"id":"926936-s-1","title":"Dosing and Indications","sub":[{"id":"926936-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Bacteremia associated with intravascular line:<\/b> (due to susceptible Gram-negative bacilli) 1 g IV once daily<\/li><li><b>Colorectal surgery - Surgical site infection; Prophylaxis:<\/b> 1 g IV 1 hour prior to surgical incision<\/li><li><b>Community acquired pneumonia:<\/b> 1 g IV\/IM once daily for 10 to 14 days<\/li><li><b>Diabetic foot infection, without osteomyelitis:<\/b> 1 g IV\/IM once daily for 7 to 14 days<\/li><li><b>Infection of skin AND\/OR subcutaneous tissue, Complicated:<\/b> 1 g IV\/IM once daily for 7 to 14 days<\/li><li><b>Infectious disease of abdomen, Complicated:<\/b> 1 g IV\/IM once daily for 5 to 14 days<\/li><li><b>Pelvic infection, acute:<\/b> 1 g IV\/IM once daily for 3 to 10 days<\/li><li><b>Urinary tract infectious disease, Complicated:<\/b> 1 g IV\/IM once daily for 10 to 14 days<\/li><\/ul>"},{"id":"926936-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>not recommended for treatment of meningitis in the pediatric population<\/li><li><b>Community acquired pneumonia:<\/b> 3 months to 12 years, 15 mg\/kg IV\/IM twice daily for 10 to 14 days (MAX dose 1 g\/day)<\/li><li><b>Community acquired pneumonia:<\/b> 13 years or older, 1 g IV\/IM once daily for 10 to 14 days<\/li><li><b>Diabetic foot infection, without osteomyelitis:<\/b> 3 months to 12 years, 15 mg\/kg IV\/IM twice daily for 7 to 14 days (MAX dose 1 g\/day)<\/li><li><b>Diabetic foot infection, without osteomyelitis:<\/b> 13 years or older, 1 g IV\/IM once daily for 7 to 14 days<\/li><li><b>Infection of skin AND\/OR subcutaneous tissue, Complicated:<\/b> 3 months to 12 years, 15 mg\/kg IV\/IM twice daily for 7 to 14 days (MAX dose 1 g\/day)<\/li><li><b>Infection of skin AND\/OR subcutaneous tissue, Complicated:<\/b> 13 years or older, 1 g IV\/IM once daily for 7 to 14 days<\/li><li><b>Infectious disease of abdomen, Complicated:<\/b> 3 months to 12 years, 15 mg\/kg IV\/IM twice daily for 5 to 14 days (MAX dose 1 g\/day)<\/li><li><b>Infectious disease of abdomen, Complicated:<\/b> 13 years or older, 1 g IV\/IM once daily for 5 to 14 days<\/li><li><b>Pelvic infection, acute:<\/b> 3 months to 12 years, 15 mg\/kg IV\/IM twice daily for 3 to 10 days (MAX dose 1 g\/day)<\/li><li><b>Pelvic infection, acute:<\/b> 13 years or older, 1 g IV\/IM once daily for 3 to 10 days<\/li><li><b>Urinary tract infectious disease, Complicated:<\/b> 3 months to 12 years, 15 mg\/kg IV\/IM twice daily for 10 to 14 days (MAX dose 1 g\/day)<\/li><li><b>Urinary tract infectious disease, Complicated:<\/b> 13 years or older, 1 g IV\/IM once daily for 10 to 14 days<\/li><\/ul>"},{"id":"926936-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>renal impairment:<\/b> CrCl 30 mL\/min or less, 500 mg IV every 24 hours<\/li><li><b>hemodialysis:<\/b> 500 mg IV every 24 hours; supplemental dose of 150 mg after hemodialysis if last dose administered within 6 hours prior to hemodialysis<\/li><li><b>geriatric:<\/b> no dosage adjustment necessary<\/li><\/ul>"},{"id":"926936-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Colorectal surgery - Surgical site infection; Prophylaxis<\/li><li>Community acquired pneumonia<\/li><li>Diabetic foot infection, without osteomyelitis<\/li><li>Infection of skin AND\/OR subcutaneous tissue, Complicated<\/li><li>Infectious disease of abdomen, Complicated<\/li><li>Pelvic infection, acute<\/li><li>Urinary tract infectious disease, Complicated<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><br\/>Bacteremia associated with intravascular line<br\/>"}]},"3":{"id":"926936-s-3","title":"Contraindications\/Warnings","sub":[{"id":"926936-s-3-9","title":"Contraindications","mono":"<ul><li>anaphylactic reaction to beta-lactam antibiotics<\/li><li>hypersensitivity to amide-type local anesthetics due to lidocaine hydrochloride used as a diluent with IM route only<\/li><li>hypersensitivity to ertapenem sodium or to any other component of the product or other drugs in the carbapenem class<\/li><\/ul>"},{"id":"926936-s-3-10","title":"Precautions","mono":"<ul><li>Immunologic:<\/li><li>-- give cautiously to patients with history of hypersensitivity to beta-lactam antibiotics such as penicillins and cephalosporins due to potentially fatal beta-lactam anaphylactic reaction<\/li><li>-- give cautiously to patients with history of sensitivity to multiple allergens due to serious and occasionally fatal anaphylactic reactions<\/li><li>Neurologic:<\/li><li>-- seizures and other CNS adverse effects have been reported especially in patients with CNS disorders such as brain lesions, history of seizures, and\/or renal impairment; decrease dose or discontinue as necessary<\/li><li>Renal:<\/li><li>-- renally impaired patients with CrCl of 30 mL\/min\/1.73 m(2) or less may be at increased risk of seizures; dose adjustment recommended<\/li><li>Other:<\/li><li>-- pediatric patients with meningitis; use not recommended due to lack of sufficient cerebrospinal fluid penetration<\/li><li>Concomitant use:<\/li><li>-- concomitant use with valproic acid or divalproex sodium<\/li><\/ul>"},{"id":"926936-s-3-11","title":"Pregnancy Category","mono":"Ertapenem: B (FDA)<br\/>"},{"id":"926936-s-3-12","title":"Breast Feeding","mono":"Ertapenem: Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"926936-s-4","title":"Drug Interactions","sub":{"1":{"id":"926936-s-4-14","title":"Major","mono":"<ul>Valproic Acid (probable)<\/ul>"},"2":{"id":"926936-s-4-15","title":"Moderate","mono":"<ul><li>Probenecid (probable)<\/li><li>Tacrolimus (probable)<\/li><\/ul>"}}},"5":{"id":"926936-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Gastrointestinal:<\/b>Abdominal pain (Adult, 3.6% to 4.3%; Pediatric, 4.7%), Constipation (Adult, 3.3% to 4%; pediatric, 2.3%), Diarrhea (Adult, 9.2% to 10.3%; Pediatric, 11.7%), Nausea (Adult, 6.4% to 8.5%; pediatric, 1.6%), Vomiting (Adult, 3.7% to 4%; Pediatric, 10.2%)<\/li><li><b>Hematologic:<\/b>Neutrophil count abnormal (5.8%)<\/li><li><b>Neurologic:<\/b>Headache (5.6% to 6.8%)<\/li><li><b>Reproductive:<\/b>Vaginitis (1.4%)<\/li><\/ul><b>Serious<\/b><br\/><b>Neurologic:<\/b>Seizure (0.5%)<br\/>"},"6":{"id":"926936-s-6","title":"Drug Name Info","sub":{"0":{"id":"926936-s-6-17","title":"US Trade Names","mono":"INVanz<br\/>"},"2":{"id":"926936-s-6-19","title":"Class","mono":"<ul><li>Antibiotic<\/li><li>Beta-Lactam<\/li><li>Carbapenem<\/li><\/ul>"},"3":{"id":"926936-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"926936-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"926936-s-7","title":"Mechanism Of Action","mono":"Ertapenem sodium is a synthetic 1-beta methyl-carbapenem with bactericidal activity. Ertapenem inhibits cell wall synthesis of gram-positive and gram-negative aerobes and anaerobes by binding to penicillin binding proteins. It withstands hydrolysis by different beta-lactamases, including penicillinases, cephalosporinases and extended spectrum beta lactamases.<br\/>"},"8":{"id":"926936-s-8","title":"Pharmacokinetics","sub":[{"id":"926936-s-8-23","title":"Absorption","mono":"<ul><li>Tmax, IM: 2.3 hours<\/li><li>Bioavailability, IM: 90%<\/li><\/ul>"},{"id":"926936-s-8-24","title":"Distribution","mono":"<ul><li>Vd, adults: 0.12 L\/kg<\/li><li>Vd, pediatrics 3 months to 12 years: 0.21 L\/kg<\/li><li>Vd, adolescents 13 to 17 years: 0.17 L\/kg<\/li><li>Protein binding, Albumin: highly bound<\/li><\/ul>"},{"id":"926936-s-8-25","title":"Metabolism","mono":"Kidney: hydrolyzed open-ring derivative: inactive <br\/>"},{"id":"926936-s-8-26","title":"Excretion","mono":"<ul><li>Fecal: 10% unchanged<\/li><li>Renal: 80% total,  38% unchanged, 37% changed<\/li><li>Dialyzable: Yes (hemodialysis), 30% removed<\/li><li>Total body clearance: adults, 1.8 L\/hr<\/li><li>Total body clearance: pediatrics, 0.64 to 1.02 mL\/min\/kg<\/li><\/ul>"},{"id":"926936-s-8-27","title":"Elimination Half Life","mono":"<ul><li>healthy young adults and adolescents, 4 hours<\/li><li>pediatric patients 3 months to 12 years, 2.5 hours  to 4 hours<\/li><li>6 hours, moderate renal insufficiency; 11 hours, advanced renal insufficiency; 14 hours ESRD<\/li><\/ul>"}]},"9":{"id":"926936-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/><ul><li>do not mix or infuse with other medications<\/li><li>do not use diluents containing dextrose<\/li><\/ul><\/li><li><b>Intramuscular<\/b><br\/><ul><li>reconstitute 1 g vial with 3.2 mL of 1% lidocaine hydrochloride injection (without epinephrine); shake thoroughly and withdraw appropriate dose<\/li><li>administer dose by deep IM injection into large muscle mass (such as the gluteal muscles or lateral part of the thigh)<\/li><li>use reconstituted solution within 1 hour of preparation<\/li><li>do not give the reconstituted IM solution intravenously<\/li><\/ul><\/li><li><b>Intravenous<\/b><br\/><ul><li>(adults) reconstitute 1 g vial with 10 mL of sterile water for injection, NS, or bacteriostatic water for injection; shake well and immediately transfer to 50 mL of NS<\/li><li>(pediatrics) reconstitute 1 g vial with 10 mL of sterile water for injection, NS, or bacteriostatic water for injection; shake well and dilute appropriate dose in NS to a final concentration of 20 mg\/mL or less<\/li><li>infuse over 30 minutes; complete infusion within 6 hours of reconstitution<\/li><li>(ADD-Vantage(R) vials) reconstitute ADD-Vantage(R) vials with ADD-Vantage(R) diluent containers containing 50 or 100 mL of NS<\/li><li>diluted solution is stable for 6 hours at room temperature or 24 hours under refrigeration; use within 4 hours after removal from refrigeration<\/li><\/ul><\/li><\/ul>"},"10":{"id":"926936-s-10","title":"Monitoring","mono":"<ul><li>fever<\/li><li>CBC<\/li><li>symptomatic improvement<\/li><li>hepatic function<\/li><\/ul>"},"11":{"id":"926936-s-11","title":"How Supplied","mono":"<b>INVanz<\/b><br\/>Injection Powder for Solution: 1 GM<br\/>"},"12":{"id":"926936-s-12","title":"Toxicology","sub":[{"id":"926936-s-12-31","title":"Clinical Effects","mono":"<b>ERTAPENEM<\/b><br\/>OVERDOSE: Overdose information is limited. Clinical effects are anticipated to be an extension of the adverse effects seen with therapeutic use. In clinical studies, one adult developed diarrhea and transient dizziness after the inadvertent administration of three 1 g doses of ertapenem in a 24-hour period. Healthy adult volunteers have experienced an increased incidence of nausea after the intravenous administration of ertapenem at a dose of 2 g over 30 minutes or 3 g over 1 to 2 hours. ADVERSE EFFECTS: Injection site reaction, diarrhea, nausea and vomiting, headache, vaginitis, phlebitis\/thrombophlebitis, and seizure (rare) have been reported.<br\/>"},{"id":"926936-s-12-32","title":"Treatment","mono":"<b>ERTAPENEM<\/b><br\/><ul><li>Decontamination: Not necessary; intravenous administration.<\/li><li>Support: Treatment is symptomatic and supportive. There is no known antidote for ertapenem following an overdose.<\/li><li>Seizure: IV benzodiazepines, barbiturates.<\/li><li>Monitoring of patient: Monitor vital signs in symptomatic patients. Monitor fluid and electrolyte status in patients with significant vomiting\/diarrhea.<\/li><li>Enhanced elimination procedure: Ertapenem is cleared by hemodialysis. When a 4-hour hemodialysis procedure was used in patients with end-stage renal insufficiency, the plasma clearance of the total fraction of ertapenem was increased by 30%. Dialysis is unlikely to be necessary after overdose, but should be considered in patients with severe toxicity.<\/li><\/ul>"},{"id":"926936-s-12-33","title":"Range of Toxicity","mono":"<b>ERTAPENEM<\/b><br\/>TOXICITY: Acute toxic dose not established. In studies, a single IV dose of 40 mg\/kg up to a maximum of 2 g did not result in toxicity in children.  In clinical studies, mild toxicity developed in an adult patients who received three 1 g doses of ertapenem in a 24-hour period. Healthy adult volunteers developed mild toxicity after ertapenem at a dose of 2 g over 30 minutes or 3 g over 1 to 2 hours. THERAPEUTIC DOSE: Adults and children 13 years of age and older: 1 g IV\/IM once daily for 3 to 14 days (depending on the type of infection); children 3 months to 12 years of age: 15 mg\/kg IV\/IM twice daily (not to exceed 1 g\/day) for up to 14 days (depending on the type of infection).<br\/>"}]},"13":{"id":"926936-s-13","title":"Clinical Teaching","mono":"<ul><li>Drug may cause diarrhea, vomiting, nausea, and headache.<\/li><li>Advise patient to immediately report signs\/symptoms of Clostridium difficile-associated diarrhea (watery or bloody stools with or without stomach cramps and fever), which may occur up to 2 or more months after the last dose of drug.<\/li><\/ul>"}}}